CAMP4 clears regulatory hurdles in Australia, Argentina for SYNGAP1 trial

CAMP4 Therapeutics said on August 13, 2026 that it has secured regulatory clearance in two jurisdictions to initiate a first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder, with trial initiation anticipated in the fourth quarter of this year.¹ Specifically, the company received clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee, as well as from Argentina's medicines regulator ANMAT, supporting initiation of the Phase 1/2 trial, with launch expected in the fourth quarter of 2026.¹

CAMP4 also said it has filed regulatory applications in the European Union and the United Kingdom aimed at expanding enrollment to more sites.¹ There are currently no approved disease-modifying treatments for SYNGAP1, according to CEO Josh Mandel-Brehm, who said the company is focused on initiating the trial and expanding into additional jurisdictions.

The company plans a virtual analyst day on September 28, 2026, that will cover the unmet clinical need in SYNGAP-1 related disorders, the design of the Phase 1/2 trial, and an update on the company's early discovery pipeline.¹

On financing, CAMP4 received $50.1 million from the fully subscribed second closing of a private placement first announced in September 2025, extending its cash runway through the end of 2028.¹ Cash and cash equivalents stood at $86.4 million as of June 30, 2026, compared to $109.5 million at the end of 2025.¹ The company said it believes current cash will be sufficient to fund planned activities through the end of 2028.¹ Net loss for the quarter was $33.5 million, versus $12.6 million a year earlier, driven mainly by a $20.9 million non-cash charge tied to a change in fair value of a derivative tranche liability from the September 2025 private placement.¹